Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Cardiotoxicity × Spironolactone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 2 Neoplasms 2 Obesity 1 Leukemia, Myeloid, Acute 1 Hyperandrogenism 1 Heart Failure 1 Critical Illness 1 Cardiotoxicity 1 Acute Kidney Injury 1

Interventions

Trastuzumab 2 Ivabradine 2 Echocardiography 2 Bisoprolol 2 salicylhydroxamic acid 1 sacubitril and valsartan sodium hydrate drug combination 1 mitoquinone 1 epicatechin gallate 1 candesartan 1 Trimetazidine 1 Therapeutics 1 Surveys and Questionnaires 1 Spironolactone 1 Secondary Prevention 1 Restraint, Physical 1 Ramipril 1 Radiotherapy 1 Perindopril 1 Nebivolol 1 Hydroxymethylglutaryl-CoA Reductase Inhibitors 1 Exercise 1 Cisplatin 1 Carvedilol 1 Atorvastatin 1 Antineoplastic Agents 1 Angiotensin-Converting Enzyme Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06005259 2023-08-22

SPIROTOX

University of Sao Paulo

Phase 4 Unknown

Heart Failure, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡